Contact Medical Information

For further medical information on Actelion treatments or PAH, please contact our Medical Information Department.

Actelion Pharmaceuticals US, Inc.
5000 Shoreline Court, Suite 200
South San Francisco, CA 94080

Phone:
1-866-ACTELION (866-228-3546)

Fax:
1-415-268-9515

Patients should always talk with their healthcare team first if there are any questions about their individual treatment.

The hours of operation for the Medical Information Department are 6:00 a.m. to 4:00 p.m. PST, Monday through Friday excluding holidays.

Automatic Request Form

Required Fields are in red.

First Name:
Last Name:
I am a:
Institution:
Address 1:
Address 2:
City:
State:	Zip:
Email:
Confirm Email:
Phone Number:
Information Request (250 Character Limit)

This form is not for reporting information about any medication side effects. To report suspected adverse reactions, contact Actelion at 1-866-ACTELION (1-866-228-3546), or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Verification:

What is ZAVESCA?

ZAVESCA is a prescription medicine taken by mouth for adults with mild to moderate type 1 Gaucher disease. ZAVESCA is used only in people who cannot be treated with enzyme replacement therapy.

Important Safety Information for Zavesca:

In clinical studies, the most common adverse events due to Zavesca included weight loss, diarrhea, and trembling in the hand (tremor). Other common adverse reactions were excess gas (flatulence), abdominal pain, and headache. The most common serious adverse reaction was tingling or numbness in the hands or feet with or without pain (peripheral neuropathy). Patients should undergo neurological examination at the start of treatment and every 6 months thereafter; Zavesca should be reassessed in patients who develop symptoms of peripheral neuropathy. Zavesca may cause fetal harm if administered to a pregnant woman. Men should maintain reliable contraceptive methods and not plan to father a child while taking Zavesca and for 3 months after discontinuing treatment.

Please see full Prescribing Information.